Comment | Published:

Challenges towards the realization of individualized cancer vaccines

Nature Biomedical Engineeringvolume 2pages566569 (2018) | Download Citation

Bringing truly personalized cancer vaccination with tumour neoantigens to the clinic will require overcoming the challenges of optimized vaccine design, manufacturing and affordability, and identification of the most suitable clinical setting.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Robbins, P. F. et al. Nat. Med. 19, 747–752 (2013).

  2. 2.

    Pardoll, D. M. Nat. Rev. Cancer 12, 252–264 (2012).

  3. 3.

    Sharma, P. & Allison, J. P. Science 348, 56–61 (2015).

  4. 4.

    Schumacher, T. N. & Schreiber, R. D. Science 348, 69–74 (2015).

  5. 5.

    Mcgranahan, N. et al. Science 351, 1463–1469 (2016).

  6. 6.

    Tran, E. et al. Science 350, 1387–1390 (2015).

  7. 7.

    Castle, J. C. et al. Cancer Res. 72, 1081–1091 (2012).

  8. 8.

    Kreiter, S. et al. Nature 520, 692–696 (2015).

  9. 9.

    Gubin, M. M. et al. Nature 515, 577–581 (2014).

  10. 10.

    Yadav, M. et al. Nature 515, 572–576 (2014).

  11. 11.

    Kreiter, S., Castle, J. C., Türeci, O. & Sahin, U. OncoImmunology 1, 768–769 (2012).

  12. 12.

    Carreno, B. M. et al. Science 348, 803–808 (2015).

  13. 13.

    Ott, P. A. et al. Nature 547, 217–221 (2017).

  14. 14.

    Sahin, U. et al. Nature 547, 222–226 (2017).

  15. 15.

    Löwer, M. et al. PLoS Comput. Biol. 8, e1002714 (2012).

  16. 16.

    Laumont, C. M. & Perreault, C. Cell. Mol. Life Sci. 75, 607–621 (2017).

  17. 17.

    Turajlic, S. et al. Lancet Oncol. 18, 1009–1021 (2017).

  18. 18.

    Balachandran, V. P. et al. Nature 551, 512–516 (2017).

  19. 19.

    Łuksza, M. et al. Nature 551, 517–520 (2017).

  20. 20.

    Khodadoust, M. S. et al. Nature 543, 723–727 (2017).

  21. 21.

    Abelin, J. G. et al. Immunity 46, 315–326 (2017).

  22. 22.

    Luo, H. et al. Bioinform. Biol. Insights https://doi.org/10.4137/BBI.S29466 (2015).

  23. 23.

    Kranz, L. M. et al. Nature 534, 396–401 (2016).

  24. 24.

    Harrison, R. P., Ruck, S., Rafiq, Q. A. & Medcalf, N. Biotechnol. Adv. 36, 345–357 (2018).

  25. 25.

    Kagermann, H. in Management of Permanent Change 23–45 (Springer Fachmedien Wiesbaden, 2015).

  26. 26.

    Türeci, O. et al. Clin. Cancer Res. 22, 1885–1896 (2016).

  27. 27.

    Chen, D. S. & Mellman, I. Nature 541, 321–330 (2017).

  28. 28.

    Melero, I. et al. Nat. Rev. Cancer 15, 457–72 (2015).

Download references

Author information

Affiliations

  1. Cluster for Individualized Immune Intervention (CI3), Mainz, Germany

    • Özlem Türeci
  2. TRON—Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany

    • Martin Löwer
    • , Barbara Schrörs
    • , Arbel Tadmor
    •  & Ugur Sahin
  3. Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany

    • Maren Lang
    •  & Ugur Sahin
  4. University Medical Center of the Johannes Gutenberg University, Mainz, Germany

    • Ugur Sahin

Authors

  1. Search for Özlem Türeci in:

  2. Search for Martin Löwer in:

  3. Search for Barbara Schrörs in:

  4. Search for Maren Lang in:

  5. Search for Arbel Tadmor in:

  6. Search for Ugur Sahin in:

Competing interests

U.S. and M.La. are employees at BioNTech AG (Mainz, Germany), a privately owned company developing individualized immunotherapies. U.S. is co-founder, stock owner and management board member of BioNTech AG. Ö.T., M.Lö., B.S., M.La., A.T. and U.S. are inventors on patents and patent applications, which are related to some of the technologies described in this article.

Corresponding author

Correspondence to Ugur Sahin.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41551-018-0266-2

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing